2022. Molecular Docking study, and In vitro Evaluation of Antitumor Activity of Some New Isoxazoline and Pyrazoline Derivatives of Nabumetone against breast cancer cell line (MCF-7). Al Mustansiriyah Journal of Pharmaceutical Sciences. 22, 3 (Oct. 2022), 24–34. DOI:https://doi.org/10.32947/ajps.v22i3.886.